CEL-SCI 将来の成長

Future 基準チェック /06

CEL-SCIは、22.5%と150%でそれぞれ年率22.5%で利益と収益が成長すると予測される一方、EPSはgrowで30.6%年率。

主要情報

22.5%

収益成長率

30.6%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	150.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	04 Sep 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NYSEAM:CVM - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2026	13	-17	N/A	N/A	2
9/30/2025	N/A	-31	-32	-29	3
9/30/2024	N/A	-39	-39	-36	3
6/30/2024	N/A	-29	-19	-19	N/A
3/31/2024	N/A	-30	-20	-20	N/A
12/31/2023	N/A	-31	-23	-23	N/A
9/30/2023	N/A	-32	-23	-23	N/A
6/30/2023	N/A	-34	-23	-23	N/A
3/31/2023	N/A	-35	-23	-23	N/A
12/31/2022	N/A	-37	-19	-18	N/A
9/30/2022	N/A	-38	-19	-18	N/A
6/30/2022	N/A	-37	-19	-18	N/A
3/31/2022	N/A	-36	-21	-18	N/A
12/31/2021	N/A	-37	-26	-20	N/A
9/30/2021	N/A	-37	-28	-19	N/A
6/30/2021	0	-34	-27	-18	N/A
3/31/2021	0	-35	-25	-16	N/A
12/31/2020	1	-33	-21	-15	N/A
9/30/2020	1	-30	-18	-15	N/A
6/30/2020	1	-30	-17	-16	N/A
3/31/2020	1	-32	-17	-17	N/A
12/31/2019	0	-29	-17	-16	N/A
9/30/2019	0	-22	-17	-16	N/A
6/30/2019	1	-32	-17	-17	N/A
3/31/2019	1	-26	-15	-15	N/A
12/31/2018	1	-24	-15	-15	N/A
9/30/2018	0	-32	-13	-13	N/A
6/30/2018	0	-22	-13	-13	N/A
3/31/2018	0	-20	N/A	-13	N/A
12/31/2017	0	-24	N/A	-12	N/A
9/30/2017	N/A	-14	N/A	-14	N/A
6/30/2017	0	-10	N/A	-17	N/A
3/31/2017	0	-10	N/A	-20	N/A
12/31/2016	0	-10	N/A	-21	N/A
9/30/2016	0	-12	N/A	-23	N/A
6/30/2016	0	-20	N/A	-22	N/A
3/31/2016	0	-21	N/A	-22	N/A
12/31/2015	1	-25	N/A	-24	N/A
9/30/2015	1	-35	N/A	-24	N/A
6/30/2015	1	-32	N/A	-24	N/A
3/31/2015	0	-30	N/A	-24	N/A
12/31/2014	0	-31	N/A	-22	N/A
9/30/2014	0	-28	N/A	-23	N/A
6/30/2014	0	-23	N/A	-21	N/A
3/31/2014	0	-25	N/A	-18	N/A
12/31/2013	0	-12	N/A	-16	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CVM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CVM今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CVM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CVM来年は収益がないと予測されています。

高い収益成長: CVM来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CVMの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

CEL-SCI 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

No longer forecast to breakeven

Forecast breakeven date moved forward to 2023

Price target decreased by 23% to US$11.50

Consensus revenue estimates fall by 33%

Forecast breakeven date pushed back to 2024

Recent updates

CEL-SCI Corporation Names Patricia B. Prichep as Chief Financial Officer

CEL-SCI Corporation Names Patricia B. Prichep as Chief Financial Officer

U.S. FDA and CEL-SCI Corporation Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence First Quarter 2025

CEL-SCI Corporation Reports New Data from Its Concluded Phase 3 Study of Multikine® (Leukocyte Interleukin, Injection)

The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI Corporation A Pediatric Waiver, Bringing Multikine One Step Closer to Future Marketing Clearance

CEL-SCI Corporation has completed a Follow-on Equity Offering in the amount of $10.7737 million.

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $10.845 million.

CEL-SCI Corporation Announces Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer

CEL-SCI Corporation Appoints Robert Watson as Chairperson of the Board

CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Value Index

New major risk - Financial position

CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine

Less than half of directors are independent

No longer forecast to breakeven

New minor risk - Market cap size

CEL-SCI Corporation, Annual General Meeting, Apr 19, 2024

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $7.75 million.

CEL-SCI Corporation has completed a Follow-on Equity Offering in the amount of $4.98 million.

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $4.98 million.

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $4.98 million.

CEL-Sci Corporation Releases Video Detailing Recent Phase 3 Findings & Its Plans to Seek Immediate Regulatory Approvals

CEL-SCI Presents the Data for the First Time at the European Society for Medical Oncology Congress in Spain

New major risk - Share price stability

Cel-Sci Files Request with the Uk's Mhra Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer

Cel-Sci Submits Scientific Advice Filing to European Medicines Agency (Ema) for Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Corporation Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination with Checkpoint Inhibitors for Head & Neck Cancer

New minor risk - Market cap size

CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed

CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed

CEL-SCI Corporation Announces Latest Results from Its Pivotal Phase 3 Study of Multikine

No longer forecast to breakeven

Forecast breakeven date moved forward to 2023

Price target decreased by 23% to US$11.50

Consensus revenue estimates fall by 33%

Forecast breakeven date pushed back to 2024

Price target increased to US$15.00

Forecast breakeven date pushed back to 2024

CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results

CEL-SCI Corporation Appoints Gail Naughton to its Board of Directors

CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Growth Index

CEL-SCI Corporation, Annual General Meeting, Jun 13, 2022

Price target increased to US$15.00

Insufficient new directors

Chief Scientific Officer recently sold US$169k worth of stock

Price target decreased to US$12.00

Forecast breakeven pushed back to 2023

Market Sentiment Around Loss-Making CEL-SCI Corporation (NYSEMKT:CVM)

Insider recently sold US$244k worth of stock

We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth

New 90-day high: US$26.54

What Does CEL-SCI's (NYSEMKT:CVM) CEO Pay Reveal?

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: US$0.82 loss per share

Breakeven On The Horizon For CEL-SCI Corporation (NYSEMKT:CVM)

CEL-SCI’s LEAPS Peptides Demonstrate Clear Survival Benefit as A Treatment for COVID-19 in Preclinical Studies

Insider notifies of intention to sell stock

Insider recently sold US$127k worth of stock

New 90-day low: US$11.56

New 90-day high: US$14.51

Analysts update estimates

Third quarter earnings released

New 90-day low - US$12.04

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘